Cytokinetics, IncorporatedCYTK
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $105.81M, growing 450.6% year-over-year. TTM net income stood at $-829.61M (34.8% contraction). Quarterly EBITDA was $-180.24M and operating income was $-183.62M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze CYTK growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters